FDA pulls high-dose Zofran from market due to cardiac risks

12/6/2012 | PhysiciansBriefing.com

The FDA said the 32-milligram, single intravenous dose of the nausea treatment Zofran, or ondansetron, will no longer be marketed because it could cause serious heart damage. A lower dose given every four hours to patients on chemotherapy will continue to be available.

View Full Article in:

PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA